Antilysophosphatidic Acid Antibodies in the Treatment of Post-TBI Neuropathic Pain
Technical Report,08 Mar 2018,07 Mar 2019
Stanford University Palo Alto United States
Pagination or Media Count:
Lysophosphatidic Acid LPA is a lipid inflammatory mediator that is released following nerve injury, including traumatic brain injury TBI. The accumulation of LPA appears to be underly at least some aspects of the sequelae to TBI, including pain and cognitive dysfunction. The goal of this project is to evaluate the therapeutic potential of a novel anti-LPA antibody Lpathomab for attenuating post-TBI pain. Thus, we propose to study the effect of Lpathomab, in preventing long-term pain sequelae due to fluid percussion-induced neurotrauma in rats. Nasal administration of Lpathomab, when compared to vehicle, produced significant levels in the brain of rats post TBI and produced a significant attenuation of the pain state following this injury.
- Medicine and Medical Research